Proactive Investors - Run By Investors For Investors

Indivior's dive puts it into buying territory, Numis believes

In the last six weeks or so, the share price of Indivior has plunged from 493p to 306p and that's a level at which Numis thinks the upside risk outweighs the downside
Generic versions of indivior's blockbuster drug for the treatment of opioid addiction are waiting in the wings

The Indivior PLC (LON:INDV) share price has fallen 20% over the last month and is now in buying territory, according to Numis Securities.

The stock has been hit by the continued threat of Indian outfit Dr Reddy producing a generic version of Suboxone, Indivior’s treatment for opioid addiction, and disappointing uptake levels for Sublocade, its injectable treatment of moderate-to-severe opioid use disorder.

READ: Indivior takes another hit as it warns of further impact from launch of Suboxone copycat

Sublocade was launched in February and although management has spoken of “some friction in the new distribution and reimbursement model” in the US, Numis was encouraged by the level at which sales were running at the end of the second quarter.

“We do not believe the company is completely through legal volatility with Dr Reddy's appeal of the injunction ongoing and Alvogen poised to gain FDA approval at some point,” Numis admitted, but nevertheless it thinks the reaction to the Sublocade launch, at least, has been overdone.

“We still forecast generic film in H2 and significant loss of share in FY19 and see any additional US cash flow from film as an upside surprise,” it said, as it upgraded the stock to ‘buy’ from ‘add’.

The broker says its 380p price target, based on a discounted cash flow model, is well supported.

Shares in Indivior currently trade at around 309p, having recovered from 266.5p on Wednesday, July 11, when it lowered full-year guidance.

FDA decision on RBP-7000 schizophrenia treatment ​due this weekend

Indivior has an injunction on Dr Reddy, preventing the Indian company from selling a generic version of Suboxone in the US, and Numis does not think the generic drugs maker will succeed in removing the injunction, although a long legal fight looks likely.

Another potential bull catalyst for the shares is approval by the US Food and Drugs Administration (FDA) of RBP-7000, its schizophrenia treatment; Numis said a decision from the FDA is expected this weekend.

As for the bear case, Numis now sees Alvogen as the biggest threat to Indivior’s future.

So far as Indivior is aware, the FDA has not yet granted tentative or final marketing authorisation to Alvogen's generic buprenorphine/naloxone film product; were it to do so, Alvogen, would be able to market its generic buprenorphine/naloxone film product in the US, but any market launch by Alvogen before a ruling on appeal would be on an "at risk" basis because Indivior would have a claim for damages against Alvogen if Indivior ultimately prevails on appeal.

“In light of the published opinion from the District Court of New Jersey, we might expect Alvogen to be better prepared than Dr Reddy’s and to be able to provide a more compelling case on the reason(s) why a potential "at-risk" launch should be allowed and why an injunction should not be granted,” Numis cautioned.


View full INDV profile View Profile

Indivior Timeline

Related Articles

PT exercises
December 20 2018
The Californian company is a bet on an industry that is in need of transformation
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use